RE:RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsNote ....I am very curious as to your credentials, so to speak. Not that I would expect you to divulge your background in biotech but unlike many here who are not paying attention, your analysis of complex discoveries and the connections to to Pela has certainly reinforced my belief that this has potential to more than dramatically change the prospects for cancer suffering individuals. I cannot make any Noteable comments on the science but I can follow, by what you have presented, the likelihood that Pela offers a transitional step forward from the traditional approach. I am very excited!